Tags

Type your tag names separated by a space and hit enter

Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data.
BJU Int. 2020 Jun 17 [Online ahead of print]BI

Abstract

OBJECTIVE

To examine national trends in the medical and surgical treatment of benign prostatic hyperplasia (BPH) using Australian Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) population data from 2000 to 2018.

PATIENTS AND METHODS

Annual data was extracted from the MBS, PBS and Australian Institute of Health and Welfare databases for the years 2000-2018. Population-adjusted rates of BPH procedures and medical therapies were calculated and compared in relation to age. Cost analysis was performed to estimate financial burden due to BPH.

RESULTS

Overall national hospital admissions due to BPH declined between 2000 and 2018, despite an increased proportion of admissions due to private procedures (42% vs 77%). Longitudinal trends in the medical management of BPH showed an increased prescription rate of dutasteride/tamsulosin combined therapy (111 vs 7649 per 100 000 men) and dutasteride monotherapy (149 vs 336 per 100 000 men) since their introduction to the PBS in 2011. Trends in BPH surgery showed an overall progressive increase in rate of total procedures between 2000 and 2018 (92 vs 133 per 100 000 men). Transurethral resection of the prostate (TURP) remained the most commonly performed surgical procedure, despite reduced utilisation since 2009 (118 vs 89 per 100 000 men), offset by a higher uptake of photoselective vaporisation of prostate, holmium:YAG laser enucleation of prostate, and later likely due to minimally invasive surgical therapies including prostatic urethral lift and ablative technologies (including Rezūm™). Financial burden due to BPH surgery has remained steady since 2009, whilst the burden due to medical therapy has risen sharply.

CONCLUSION

Despite reduced national BPH-related hospitalisations, overall treatment for BPH has increased due to medical therapy and surgical alternatives to TURP. Further exploration into motivators for particular therapies and effect of medical therapy on BPH progression in clinical practice outside of clinical trials is warranted.

Authors+Show Affiliations

Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. Department of Surgery, Austin Health, The University of Melbourne, Parkville, Victoria, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. Andro Urology Centre, Brisbane, Queensland, Australia.Department of Surgery, Austin Health, The University of Melbourne, Parkville, Victoria, Australia.Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.Department of Urology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. Nepean Urology Research Group, Nepean Hospital, Kingswood, New South Wales, Australia. Centre for Clinical Research, The University of Queensland, Herston, Queensland, Australia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32558340

Citation

Morton, Andrew, et al. "Management of Benign Prostatic Hyperplasia in the 21st Century: Temporal Trends in Australian Population-based Data." BJU International, 2020.
Morton A, Williams M, Perera M, et al. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU Int. 2020.
Morton, A., Williams, M., Perera, M., Teloken, P. E., Donato, P., Ranasinghe, S., Chung, E., Bolton, D., Yaxley, J., & Roberts, M. J. (2020). Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU International. https://doi.org/10.1111/bju.15098
Morton A, et al. Management of Benign Prostatic Hyperplasia in the 21st Century: Temporal Trends in Australian Population-based Data. BJU Int. 2020 Jun 17; PubMed PMID: 32558340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. AU - Morton,Andrew, AU - Williams,Michael, AU - Perera,Marlon, AU - Teloken,Patrick E, AU - Donato,Peter, AU - Ranasinghe,Sachinka, AU - Chung,Eric, AU - Bolton,Damien, AU - Yaxley,John, AU - Roberts,Matthew J, Y1 - 2020/06/17/ PY - 2020/04/17/accepted PY - 2020/6/20/entrez KW - Medicare KW - benign prostatic hyperplasia KW - minimally invasive KW - national trends KW - surgical procedures KW - transurethral resection of prostate JF - BJU international JO - BJU Int. N2 - OBJECTIVE: To examine national trends in the medical and surgical treatment of benign prostatic hyperplasia (BPH) using Australian Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) population data from 2000 to 2018. PATIENTS AND METHODS: Annual data was extracted from the MBS, PBS and Australian Institute of Health and Welfare databases for the years 2000-2018. Population-adjusted rates of BPH procedures and medical therapies were calculated and compared in relation to age. Cost analysis was performed to estimate financial burden due to BPH. RESULTS: Overall national hospital admissions due to BPH declined between 2000 and 2018, despite an increased proportion of admissions due to private procedures (42% vs 77%). Longitudinal trends in the medical management of BPH showed an increased prescription rate of dutasteride/tamsulosin combined therapy (111 vs 7649 per 100 000 men) and dutasteride monotherapy (149 vs 336 per 100 000 men) since their introduction to the PBS in 2011. Trends in BPH surgery showed an overall progressive increase in rate of total procedures between 2000 and 2018 (92 vs 133 per 100 000 men). Transurethral resection of the prostate (TURP) remained the most commonly performed surgical procedure, despite reduced utilisation since 2009 (118 vs 89 per 100 000 men), offset by a higher uptake of photoselective vaporisation of prostate, holmium:YAG laser enucleation of prostate, and later likely due to minimally invasive surgical therapies including prostatic urethral lift and ablative technologies (including Rezūm™). Financial burden due to BPH surgery has remained steady since 2009, whilst the burden due to medical therapy has risen sharply. CONCLUSION: Despite reduced national BPH-related hospitalisations, overall treatment for BPH has increased due to medical therapy and surgical alternatives to TURP. Further exploration into motivators for particular therapies and effect of medical therapy on BPH progression in clinical practice outside of clinical trials is warranted. SN - 1464-410X UR - https://www.unboundmedicine.com/medline/citation/32558340/Management_of_benign_prostatic_hyperplasia_in_the_21st_century:_temporal_trends_in_Australian_population-based_data L2 - https://doi.org/10.1111/bju.15098 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.